Legato Capital Management LLC Boosts Stock Position in Repligen Corporation $RGEN

Legato Capital Management LLC raised its position in Repligen Corporation (NASDAQ:RGEN) by 31.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,100 shares of the biotechnology company’s stock after purchasing an additional 5,100 shares during the period. Legato Capital Management LLC’s holdings in Repligen were worth $2,820,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC raised its position in shares of Repligen by 1.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after buying an additional 75 shares during the last quarter. Hilltop National Bank grew its stake in Repligen by 8.0% in the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after acquiring an additional 95 shares during the period. ProShare Advisors LLC raised its holdings in Repligen by 4.3% in the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 96 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Repligen by 17.0% during the 3rd quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 97 shares during the period. Finally, State of Michigan Retirement System lifted its stake in shares of Repligen by 0.8% during the 2nd quarter. State of Michigan Retirement System now owns 12,553 shares of the biotechnology company’s stock worth $1,561,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of a number of recent analyst reports. UBS Group lowered their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Wells Fargo & Company lowered their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 17th. Finally, Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $174.58.

Repligen Trading Down 2.9%

NASDAQ RGEN opened at $124.97 on Tuesday. The firm has a market capitalization of $7.03 billion, a price-to-earnings ratio of 147.02, a PEG ratio of 2.50 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. Repligen Corporation has a one year low of $102.96 and a one year high of $175.77. The company’s 50 day moving average price is $153.37 and its 200 day moving average price is $147.10.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The company had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, sell-side analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.